BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 35259043)

  • 21. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia.
    Cox MJ; Lucien F; Sakemura R; Boysen JC; Kim Y; Horvei P; Manriquez Roman C; Hansen MJ; Tapper EE; Siegler EL; Forsman C; Crotts SB; Schick KJ; Hefazi M; Ruff MW; Can I; Adada M; Bezerra E; Kankeu Fonkoua LA; Nevala WK; Braggio E; Ding W; Parikh SA; Kay NE; Kenderian SS
    Mol Ther; 2021 Apr; 29(4):1529-1540. PubMed ID: 33388419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide.
    Works M; Soni N; Hauskins C; Sierra C; Baturevych A; Jones JC; Curtis W; Carlson P; Johnstone TG; Kugler D; Hause RJ; Jiang Y; Wimberly L; Clouser CR; Jessup HK; Sather B; Salmon RA; Ports MO
    Mol Cancer Ther; 2019 Dec; 18(12):2246-2257. PubMed ID: 31395689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.
    Kuramitsu S; Ohno M; Ohka F; Shiina S; Yamamichi A; Kato A; Tanahashi K; Motomura K; Kondo G; Kurimoto M; Senga T; Wakabayashi T; Natsume A
    Cancer Gene Ther; 2015 Oct; 22(10):487-95. PubMed ID: 26450624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Driving Out Chronic Lymphocytic Leukemia With CAR T Cells.
    Kharfan-Dabaja MA; Yassine F; Gadd ME; Qin H
    Transplant Cell Ther; 2022 Jan; 28(1):5-17. PubMed ID: 34656807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Fraietta JA; Beckwith KA; Patel PR; Ruella M; Zheng Z; Barrett DM; Lacey SF; Melenhorst JJ; McGettigan SE; Cook DR; Zhang C; Xu J; Do P; Hulitt J; Kudchodkar SB; Cogdill AP; Gill S; Porter DL; Woyach JA; Long M; Johnson AJ; Maddocks K; Muthusamy N; Levine BL; June CH; Byrd JC; Maus MV
    Blood; 2016 Mar; 127(9):1117-27. PubMed ID: 26813675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings.
    Todorovic Z; Todorovic D; Markovic V; Ladjevac N; Zdravkovic N; Djurdjevic P; Arsenijevic N; Milovanovic M; Arsenijevic A; Milovanovic J
    Curr Oncol; 2022 May; 29(5):3647-3657. PubMed ID: 35621683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges and opportunities of CAR T-cell therapies for CLL.
    Zhao Z; Grégoire C; Oliveira B; Chung K; Melenhorst JJ
    Semin Hematol; 2023 Jan; 60(1):25-33. PubMed ID: 37080707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lenalidomide abrogates the survival effect of bone marrow stromal cells in chronic lymphocytic leukemia.
    Kriston C; Hernádfői M; Plander M; Márk Á; Takács F; Czeti Á; Szalóki G; Szabó O; Matolcsy A; Barna G
    Hematol Oncol; 2021 Oct; 39(4):513-520. PubMed ID: 34013974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?
    Davila ML; Brentjens R
    Hematol Oncol Clin North Am; 2013 Apr; 27(2):341-53. PubMed ID: 23561477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
    Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8
    van Bruggen JAC; Martens AWJ; Fraietta JA; Hofland T; Tonino SH; Eldering E; Levin MD; Siska PJ; Endstra S; Rathmell JC; June CH; Porter DL; Melenhorst JJ; Kater AP; van der Windt GJW
    Blood; 2019 Jul; 134(1):44-58. PubMed ID: 31076448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
    Fraietta JA; Lacey SF; Orlando EJ; Pruteanu-Malinici I; Gohil M; Lundh S; Boesteanu AC; Wang Y; O'Connor RS; Hwang WT; Pequignot E; Ambrose DE; Zhang C; Wilcox N; Bedoya F; Dorfmeier C; Chen F; Tian L; Parakandi H; Gupta M; Young RM; Johnson FB; Kulikovskaya I; Liu L; Xu J; Kassim SH; Davis MM; Levine BL; Frey NV; Siegel DL; Huang AC; Wherry EJ; Bitter H; Brogdon JL; Porter DL; June CH; Melenhorst JJ
    Nat Med; 2018 May; 24(5):563-571. PubMed ID: 29713085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).
    Shanafelt TD; Ramsay AG; Zent CS; Leis JF; Tun HW; Call TG; LaPlant B; Bowen D; Pettinger A; Jelinek DF; Hanson CA; Kay NE
    Blood; 2013 May; 121(20):4137-41. PubMed ID: 23493782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.
    Sportoletti P; De Falco F; Del Papa B; Baldoni S; Guarente V; Marra A; Dorillo E; Rompietti C; Adamo FM; Ruggeri L; Di Ianni M; Rosati E
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia.
    Mancikova V; Smida M
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs).
    Cassioli C; Patrussi L; Valitutti S; Baldari CT
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cells.
    Yang S; Huang X; Gale RP
    Blood Rev; 2022 Jan; 51():100884. PubMed ID: 34489116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellular Immunotherapy in B-Cell Malignancy.
    Schwarzbich MA; Witzens-Harig M
    Oncol Res Treat; 2017; 40(11):674-681. PubMed ID: 29065420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD23 antigen regulation and signaling in chronic lymphocytic leukemia.
    Fournier S; Delespesse G; Rubio M; Biron G; Sarfati M
    J Clin Invest; 1992 Apr; 89(4):1312-21. PubMed ID: 1532590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.